

**PM-CAR1037 BCMA-4-TM8-41BB-CD3 ZETA**

Ready-to use-CAR-T cells

Our **CAR-T new product development programs are being designed for pre-clinical and future clinical applications.**

**CAR-T cells can be used for:**

1. Compound screening
2. Antibody screening
3. Co-stimulatory and activation domain comparison
4. Personalized medicine and donor variations for CAR-T screening
5. Checkpoint inhibitors
6. Safety switches and regulators of CAR-T functions
7. Pre-clinical in vivo models
8. Treg and T memory cells in CAR-T setting
9. CAR-T signaling, tumor microenvironment
10. Proof of concept studies for clinical trials

The structure of CAR:

BCMA protein is often overexpressed in multiple myeloma.


**BCMA ScFv-41BB-CD3 Zeta Car**

Figure 1. CAR-T cells expressing the above constructs are available from AMSBIO targeting BCMA antigen. BCMA-CAR had 4-1BB co-activation domain

To date, we have generated 2nd generation CAR and CAR controls (as shown in Figure 1). We have also generated CAR-T cells and CAR-NK (Natural Killer) effector cells against cancer target cells that show excellent functionality, including dose-dependent and target cell-specific cytotoxic activity.

These CAR-T cells can be tested with target cells in cytotoxic assays and used for testing modulators of immune checkpoint inhibitors (PD-1, CTLA-4 pathways), activators of immune response, or small molecules affecting T-cell or T-reg activity.

AMSBIO | [www.amsbio.com](http://www.amsbio.com) | [info@amsbio.com](mailto:info@amsbio.com)

 **UK & Rest of the World**  
184 Park Drive, Milton Park  
Abingdon OX14 4SE, UK  
T: +44 (0)1235 828 200  
F: +44 (0) 1235 820 482

 **North America**  
1035 Cambridge Street,  
Cambridge, MA 02141  
T: +1 (617) 945-5033 or  
T: +1 (800) 987-0985  
F: +1 (617) 945-8218

 **Germany**  
Bockenheimer Landstr. 17/19  
60325 Frankfurt/Main  
T: +49 (0) 69 779099  
F: +49 (0) 69 13376880

 **Switzerland**  
Centro Nord-Sud 2E  
CH-6934 Bioggio-Lugano  
T: +41(0) 91 604 55 22  
F: +41(0) 91 605 17 85

# PM-CAR1037 BCMA-4-TM8-41BB-CD3 ZETA

Ready-to use-CAR-T cells

## Data





Figure 2. RTCA cytotoxicity activity of effector BCMA-4-1BB and BCMA-CD28-CD3-CAR-T cells against CHO-BCMA cells (top panel) and CHO cells (lower panel). Effector cells: Target cells ratio=10:1.

AMSBIO | [www.amsbio.com](http://www.amsbio.com) | [info@amsbio.com](mailto:info@amsbio.com)

**UK & Rest of the World**  
 184 Park Drive, Milton Park  
 Abingdon OX14 4SE, UK  
 T: +44 (0)1235 828 200  
 F: +44 (0) 1 235 820 482

**North America**  
 1035 Cambridge Street,  
 Cambridge, MA 02141  
 T: +1 (617) 945-5033 or  
 T: +1 (800) 987-0985  
 F: +1 (617) 945-8218

**Germany**  
 Bockenheimer Landstr. 17/19  
 60325 Frankfurt/Main  
 T: +49 (0) 69 779099  
 F: +49 (0) 69 13376880

**Switzerland**  
 Centro Nord-Sud 2E  
 CH-6934 Bioggio-Lugano  
 T: +41(0) 91 604 55 22  
 F: +41(0) 91 605 17 85